Investment, Funding & Disinvestments

The announcement comes as part of Dubai’s Economic Agenda D33, which aims to position the emirate as a global healthcare destination.

The healthcare zone centers around Thumbay University Hospital Dubai, which launches in Phase One with specialized services including renal dialysis, cardiology, orthopedics, and rehabilitation.

The acquisition gives Lilly access to Orna’s innovative platform, which combines circular RNA (circRNA) with lipid nanoparticle-based therapies.

The expansion also aligns with the government’s National Cancer Plan for England, which focuses on accelerating patient diagnosis and improving access to treatment nationwide.

The new San Diego facility will function as a critical node in Novartis’s integrated global research network, connecting seamlessly with existing research hubs in Basel, Switzerland, and Cambridge, Massachusetts.

It encompasses the capacity to develop, manufacture, and discover through strong partnerships among government, academia, industry, and regulatory bodies.

The deal centers on one of SanegeneBio’s innovative RNAi programs and grants Genentech exclusive worldwide rights to develop and bring the treatment to market.

The divestment positions Halo to focus on expanding into more complex drug-product manufacturing services while strengthening its presence in the sterile CDMO market.

The acquisition encompasses MDCO’s complete portfolio of ophthalmic devices, including intraocular lenses (IOL), implantable contact lenses (Phakic Lens), and various refractive device platforms.

CSPC is expected to receive an additional USD3.5 billion if the programs successfully meet development and regulatory milestones, in addition to royalties from any drugs approved under the partnership.